Patents Assigned to GEMVAX & KAEL CO., LTD.
-
Patent number: 10463708Abstract: A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.Type: GrantFiled: December 22, 2015Date of Patent: November 5, 2019Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 10383926Abstract: Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1?, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.Type: GrantFiled: June 5, 2014Date of Patent: August 20, 2019Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Publication number: 20190142894Abstract: The present specification relates to a composition containing a peptide having effects of increasing telomerase activity and extending a telomere, and more specifically, to a composition containing a telomerase-derived peptide, thereby being effective for preventing, alleviating and treating diseases, caused by a decrease in telomerase activity or a reduction in telomere length, and symptoms caused by cell aging or damage. According to one aspect to the present invention, the peptide increases telomerase activity and is effective for extending a telomere, and thus a method for treating diseases induced by an abnormal decrease in telomerase activity and by the length reduction or loss of a telomere and alleviating symptoms caused thereby can be provided.Type: ApplicationFiled: April 7, 2017Publication date: May 16, 2019Applicant: GEMVAX & KAEL CO., LTD.Inventors: Sang Jae KIM, Kyuyong LEE, Seong Ho KOH
-
Patent number: 10245327Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: December 9, 2016Date of Patent: April 2, 2019Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 10206981Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: GrantFiled: November 17, 2016Date of Patent: February 19, 2019Assignee: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20190030137Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: July 2, 2018Publication date: January 31, 2019Applicant: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20190032032Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.Type: ApplicationFiled: July 4, 2016Publication date: January 31, 2019Applicant: GemVax & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20180318383Abstract: The present invention relates to a composition for neuronal loss prevention and regeneration and, more specifically, to a composition for neuronal loss prevention and regeneration, containing a telomerase-derived peptide so as to be effective on known diseases caused by neuronal loss and regeneration inability. According to the present invention, the peptide shows preventive and treatment effects on neuronal loss and regeneration inability diseases including Alzheimer's disease, and thus a novel method for treating neuronal loss and regeneration inability diseases can be provided.Type: ApplicationFiled: November 11, 2016Publication date: November 8, 2018Applicant: GEMVAX & KAEL CO., LTD.Inventors: Sang Jae KIM, Seong Ho KOH, Kyuyong LEE
-
Patent number: 10039811Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating a variety of different types of inflammatory diseases.Type: GrantFiled: November 4, 2016Date of Patent: August 7, 2018Assignee: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Patent number: 10034922Abstract: A peptide having angiogenesis inhibition activity and pharmaceutical composition comprising thereof is described. More specifically, the application relates to the pharmaceutical composition for inhibiting angiogenesis comprising the peptide as a peptide derived from telomerase.Type: GrantFiled: November 21, 2014Date of Patent: July 31, 2018Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Publication number: 20180207241Abstract: The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-? signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.Type: ApplicationFiled: March 15, 2018Publication date: July 26, 2018Applicant: GEMVAX & KAEL CO., LTDInventor: Sang Jae KIM
-
Patent number: 9937240Abstract: The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-? signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.Type: GrantFiled: April 10, 2015Date of Patent: April 10, 2018Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 9907837Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.Type: GrantFiled: May 10, 2013Date of Patent: March 6, 2018Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 9907838Abstract: The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury.Type: GrantFiled: April 18, 2014Date of Patent: March 6, 2018Assignee: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae Kim
-
Patent number: 9902945Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: September 17, 2013Date of Patent: February 27, 2018Assignee: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae Kim
-
Publication number: 20180036384Abstract: The present invention relates to a pharmaceutical composition for preventing and treating hearing loss. More particularly, the present invention relates to a composition including a telomerase-derived peptide, the composition being effective in the treatment and prevention of hearing loss due to an ototoxic drug. A peptide having a sequence of SEQ ID NO: 1, a peptide having 80% or more sequence homology to the sequence, or a fragment thereof, according to the present invention, has an excellent effect in the treatment and prevention of hearing loss due to an ototoxic drug.Type: ApplicationFiled: February 18, 2016Publication date: February 8, 2018Applicant: GemVax & KAEL CO. LTD.Inventor: Sang Jae KIM
-
Publication number: 20170360870Abstract: The present specification discloses a pharmaceutical composition for preventing or treating ophthalmopathy. More particularly, disclosed is a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy. The disclosed peptide, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.Type: ApplicationFiled: December 22, 2015Publication date: December 21, 2017Applicant: Gemvax & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Patent number: 9844584Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis. Also disclosed are a pharmaceutical composition or a food composition containing the peptide as an active ingredient, a usage of the peptide for preventing or treating sepsis, and a kit comprising the peptide and instructions.Type: GrantFiled: May 10, 2013Date of Patent: December 19, 2017Assignee: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae Kim
-
Patent number: 9757473Abstract: A cell-penetrating peptide, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate is described. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained.Type: GrantFiled: July 11, 2014Date of Patent: September 12, 2017Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 9730984Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a superior effect of treating and preventing rheumatoid arthritis with minimized side effect.Type: GrantFiled: May 10, 2013Date of Patent: August 15, 2017Assignee: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae Kim